Perspective
Our work in Perspective
-
California Should Lead on Health Technology Assessment
California has the opportunity to take the lead on incorporating value-based pricing of health technology in the state healthcare system.
Categorized in -
We Should Double Down on Treatments for Those at High Risk Instead of Pushing Boosters and Tests for Everyone
Billions of dollars now committed to home-testing masses of people could be saved if we tested only the symptomatic. Those funds would be better spent supporting access to affordable COVID treatment for people with a high risk of hospitalization.
Categorized in -
Who Are the Winners in the No Surprises Act?
With the No Surprises Act set to take effect January 1, HHS is resisting a push from some doctor groups to weaken implementation rules of the legislation, and that’s a good thing. The law is a big win for patients, employers, and consumers.
Categorized in -
Middlemen, Not Drug Companies, Are Pushing Up Insulin Prices, and Congress Doesn’t Have the Right Plan to Fight Back
Congress should take advantage of the current political climate and start reining in the intermediaries in the drug distribution system.
Categorized in -
How COVID Can Help Us Refocus on the How and Why of Value Assessment
The limitations of conventional approaches to value assessment are particularly clear when reflecting on our experience with the COVID-19 pandemic.
Categorized in -
Economic Incentives for Administrative Simplification
In the US health care system, payers, health systems, physicians, other clinicians, drug companies, pharmacies, and pharmacy benefit managers all earn more revenue because of administrative complexity.
Categorized in -
The Hidden Cost of Covid-19: Years of Life Lost Among the Young
The focus on deaths affecting mainly the elderly is unfortunate because it likely created a false sense of security among the young.
Categorized in -
Biosimilars Competition Helps Patients More Than Generic Competition
Well-intended proposals to have the government intervene and “incentivize” biosimilar uptake may result in less price competition, not more.
Categorized in -
Federal Government Should Advise on Drug Negotiations, Not Run Them
Schaeffer Center experts Karen Mulligan and Darius Lakdawalla argue that the Department of Health and Human Services should help advice drug price negotiations instead of running them.
Categorized in
